Who is sponsoring NCT03307122?

NCT03307122 is sponsored by Société des Produits Nestlé (SPN).

What drugs are being tested in NCT03307122?

Interventions in NCT03307122: Routine Infant Formula 1, Routine Infant Formula 2.

What condition does NCT03307122 study?

NCT03307122 studies Healthy, Full-term Infants Who Are Formula-fed.

Is NCT03307122 still recruiting?

NCT03307122 is currently completed. Last updated 23 May 2018.

Last reviewed 2018-05-23 · How we verify

NCT03307122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastrointestinal Tolerance Evaluation of an Infant Formula

Completed NA Last updated 23 May 2018

What this trial tests

NA trial testing Routine Infant Formula 1 in Healthy, Full-term Infants Who Are Formula-fed in 79 participants. Completed in 19 January 2018.

Timeline

21 September 2017

Primary endpoint
19 January 2018

19 January 2018

Quick facts

Lead sponsor	Société des Produits Nestlé (SPN)
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	79
Start date	21 September 2017
Primary completion	19 January 2018
Estimated completion	19 January 2018
Sites	8 locations across United States

Drugs / interventions tested

Routine Infant Formula 1
Routine Infant Formula 2

Conditions studied

Healthy, Full-term Infants Who Are Formula-fed — all drugs for Healthy, Full-term Infants Who Are Formula-fed →

Sponsor

Société des Produits Nestlé (SPN) — full company profile →

Who can join

Adults 9 Days to 19 Days, any sex, with Healthy, Full-term Infants Who Are Formula-fed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, double-blind, randomized study of 2 infant formulas.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

2'-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With <i>Bifidobacterium lactis</i>: A Randomized Controlled Trial.
Storm HM, Shepard J, Czerkies LM, Kineman B, et al · · 2019 · cited 28× · PMID 30906817 · DOI 10.1177/2333794x19833995
Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.
Duman H, Bechelany M, Karav S. · · 2024 · cited 18× · PMID 39796552 · DOI 10.3390/nu17010118

Verify or expand the search:

Other Société des Produits Nestlé (SPN) trials

Trials by the same sponsor.

NCT07312201 — Oral Nutritional Supplementation in Children With Growth Concerns · NA · not yet recruiting
NCT07378111 — Vegetarian Tube Feed Study · NA · not yet recruiting
NCT07439718 — The Effects of an Oral Nutritional Intervention on the Small Intestine Microbiome · NA · recruiting
NCT07341464 — Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends · NA · recruiting
NCT07127198 — Tolerance and Appetite Reduction of a Nutritional Solution With Intragastric Gelation Properties · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03307122 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Société des Produits Nestlé (SPN)
Last refreshed: 23 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03307122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing